---
title: "H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305706151.md"
description: "H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical (BMRN) with a $60 price target. This follows a Hold from Stifel Nicolaus and contrasts with a Buy rating maintained by Evercore ISI on November 13."
datetime: "2026-11-16T17:35:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305706151.md)
  - [en](https://longbridge.com/en/news/305706151.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305706151.md)
generator: "portal-rs"
---

# H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical today and set a price target of $60.00.

Kapoor covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Incyte, and Ionis Pharmaceuticals. According to TipRanks, Kapoor has an average return of 6.6% and a 37.92% success rate on recommended stocks. 

In addition to H.C. Wainwright, BioMarin Pharmaceutical also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued on November 3. However, on November 13, Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN).

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [BioMarin Pharmaceutical (BMRN) Following Q3 Results And A Guidance Cut Is It A Bargain](https://longbridge.com/en/news/305152575.md)
- [BioMarin Pharmaceutical's (BMRN) Neutral Rating Reiterated at HC Wainwright](https://longbridge.com/en/news/304149061.md)
- [BioMarin’s Resilient Growth Outlook Supports Buy Rating Despite Price-Target Cut to $89](https://longbridge.com/en/news/304115875.md)
- [BioMarin Pharmaceutical (BMRN) Expected to Post Earnings on Monday](https://longbridge.com/en/news/302249849.md)
- [Is it time to buy at the bottom? Jensen Huang is still being smeared. Anthropic's IPO = a horror story.](https://longbridge.com/en/news/306347695.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**